<DOC>
	<DOCNO>NCT00780793</DOCNO>
	<brief_summary>Remission nowadays recommend therapeutic objective rheumatoid arthritis . Once objective achieve thanks TNF-blockers , optimal therapeutic strategy remain unclear , either therapeutic maintenance progressive DMARD tapering ( non quantify risk disease flare ) . STRASS 2-arm randomize controlled trial aim compare 2 strategy ( DMARD maintenance progressive space TNF-blocker injection ) term remission maintenance , relapse risk , safety issue economic consequence 18 month . The inclusion period 18 month , September 2008 February 2010 .</brief_summary>
	<brief_title>Spacing TNF-blocker Injections Rheumatoid Arthritis Study</brief_title>
	<detailed_description>Rationale : Clinical remission therapeutic objective rheumatoid arthritis , recommend professional practice guideline . Once objective achieve subcutaneous TNF-blockers , maintenance treatment - highly efficacious expensive potentially toxic - debate . To date , reliable data available estimate risk - benefice ratio associate either maintenance tapering . Objectives : In RA patient remission , study aim : 1 . To compare RA inflammatory activity base repeat measure Disease Activity Score ( DAS ) depend 2 therapeutic scheme : ( M ) maintenance unchanged TNF-blockers ( S ) taper TNF-blocker dos progressive space subcutaneous injection accord predefined algorithm ; 2 . To estimate cost - effectiveness ratio TNF-blocker spacing compare TNF-blocker maintenance . Inclusion criterion : - Patients age 18 , diagnose RA accord 1987 ACR classification criterion ; - RA treat subcutaneous TNF-blockers ( etanercept adalimumab ) stable standard dosage 1 year , monotherapy associate stable conventional DMARD ; - RA clinical remission , define stable DAS28 ≤ 2.6 6 month , without structural damage progression X-rays ( local reading treat rheumatologist ) ; Exclusion criterion : - Treatment steroid ; - progress disease X-rays year precede trial ; - surgery plan 18 coming month ; - pregnancy ; - on-going neoplastic disease ; - auto-immune disorder different RA ; - inability speak understand French ; - absence sign informed consent ; - absence medical insurance coverage . Sample size calculation : 250 patient , 125 arm . Centers : 22 inclusion center France . Research duration : 3 year . Participation duration patient : 18 month . Inclusion period duration : 18 month ( Sep 2008 - Feb 2010 ) . Methods : Equivalence trial , prospective , randomize , control versus usual care , patient remain blind tested hypothesis . Investigators assess disease activity remain blind protocol arm . The statistical analysis base mixed linear model take account repeat data . Randomization : Computer-assisted randomization ( CleanWeb software ) block unequal size , stratify inclusion center TNF-blocker molecule . Primary endpoint : RA inflammatory activity 18 month estimate DAS28 repeat measure . Secondary endpoint : - RA inflammatory activity 18 month estimate DAS44 repeat measure ; - Cost - Effectiveness ratio calculate : ( CostMaintenance - CostSpacing ) / ( EfficacyMaintenance - EfficacySpacing ) ; - Relapse rate 18 month base Kaplan Meier survival analysis ; - Functional impairment base HAQ index ; - Health-related quality life SF-36 ; - Utility base EQ-5D instrument ; - Structural damage progression 18 month assess van der HEIJDE-modified Sharp score ( SHS ) ; - Safety ; - Determinants maintain remission relapse TNF-blocker injection space . Research time sheet : Clinical , biological image follow-up base guidelines-recommended RA follow-up . Biological work-ups specifically dedicate research represent 80 mL . The others part usual care may perform non-hospital laboratory . Expected result perspective : The trial aim test feasibility risk - benefit ratio step-down strategy TNF-blockers course RA .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Patients age 18 , diagnose RA accord 1987 ACR classification criterion ; RA treat subcutaneous TNFblockers ( étanercept adalimumab ) stable standard dosage 1 year , monotherapy associate stable conventional DMARD ; RA clinical remission , define stable DAS28 ≤ 2.6 6 month , without structural damage progression Xrays ( local reading treat rheumatologist ) ; Treatment steroid ; progress disease Xrays year precede trial ; surgery plan 18 coming month ; pregnancy ; ongoing neoplastic disease ; autoimmune disorder different RA ; inability speak understand French ; absence sign informed consent ; absence medical insurance coverage .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>Remission</keyword>
	<keyword>Therapeutic strategy</keyword>
	<keyword>DMARDs</keyword>
	<keyword>Biological agent</keyword>
</DOC>